Stock ACIU AC IMMUNE SA
Add to a list
To use this feature you must be a member
Log inSign up

Highlights AC Immune SA

Equities

ACIU

CH0329023102

Real-time Estimate Cboe BZX
Other stock markets
 14:47:16 14/05/2024 BST 		5-day change 1st Jan Change
3.37 USD +2.12% Intraday chart for AC Immune SA +35.71% -35.40%
05-13 Sector Update: Health Care Stocks Mixed Late Afternoon MT
05-13 Sector Update: Health Care MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Mixed Late Afternoon
MT
Sector Update: Health Care
MT
Top Midday Gainers
MT
AC Immune Enters Licensing Deal for Alzheimer's Disease Drug Candidate
MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Ahead of Key Inflation Reports
MT
Top Premarket Gainers
MT
Takeda Pharmaceutical, AC Immune Agree to Option and Licence Agreement, Including on Alzheimer's Treatment Candidate
MT
AC Immunity Shares Soar on Exclusive License Deal with Takeda
DJ
AC Immune SA Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
AC Immune SA Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Roche terminates licensing agreement with AC Immune
CF
AC Immune SA Announces Termination of the Research Collaboration and License Agreement with Genentech, Inc
CI
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson's Diseases
CI
AC Immune SA Announces its Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial
CI
AC Immune SA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
AC Immune SA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Companies in Alzheimer's race after US nod for Eisai/Biogen drug
RE
AC Immune Receives FDA Fast-Track Designation for Investigational Alzheimer's Treatment; Shares Rise Pre-Bell
MT
AC Immune SA Receives FDA Fast Track Designation for Anti-Amyloid-Beta Active Immunotherapy, ACI-24 060, to Treat Alzheimer's Disease
CI
AC Immune SA Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ACIU Stock
  4. News AC Immune SA
  5. Highlights